Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats

Xenobiotica

Volumn 41, Issue 12, 2011, Pages 1100-1107

  Lee, Kyeong Ryoon ^a   Chae, Yoon Jee ^a   Koo, Tae Sung ^b  

^a Seoul National University   (South Korea)

^b SK Biopharmaceuticals Co   (South Korea)

Author keywords

Atypical anti psychotic; Bioavailability; Lurasidone; Metabolism; Pharmacokinetics; Tissue distribution

Indexed keywords

LURASIDONE; ZIPRASIDONE;

ANIMAL EXPERIMENT; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG STRUCTURE; LIVER MICROSOME; MALE; NONHUMAN; PLASMA PROTEIN BINDING; RAT; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; ANIMALS; ANTIPSYCHOTIC AGENTS; INJECTIONS, INTRAVENOUS; ISOINDOLES; MALE; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; REFERENCE STANDARDS; THIAZOLES;

RATTUS;

EID: 80655144981     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2011.603388     Document Type: Article

References (20)

1. Andreasen NC, Nopoulos P, Schultz S, Miller D, Gupta S, Swayze V, Flaum M. (1994). Positive and negative symptoms of schizophrenia: past, present, and future. Acta Psychiatr Scand Suppl 384:51-59. (Pubitemid 24356888)
2. Citrome L. (2011a). Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic. Clin Schizophr Relat Psychoses 4:251-257.
3. Citrome L. (2011b). Lurasidone for schizophrenia: a review of the efcacy and safety profle for this newly approved second-generation antipsychotic. Int J Clin Pract 65:189-210.
4. Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095. (Pubitemid 23211439)
5. Enomoto T, Ishibashi T, Tokuda K, Ishiyama T, Toma S, Ito A. (2008). Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. Behav Brain Res 186:197-207. (Pubitemid 350122756)
6. FDA U. (2001). Guidance for industry: bioanalytical method validation. Rockville, MD: CDER.
7. Gründer G, Hippius H, Carlsson A. (2009). Te 'atypicality' of antipsychotics: a concept re-examined and re-defned. Nat Rev Drug Discov 8:197-202.
8. Haddad P. (2005). Weight change with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol (Oxford) 19:16-27. (Pubitemid 44567855)
9. Houston JB, Carlile DJ. (1997). Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab Rev 29:891-922. (Pubitemid 28133451)
10. Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, Matsumoto K, Nishikawa H, Ueda Y, Toma S, Oki H, Tanno N, Saji I, Ito A, Ohno Y, Nakamura M.(2010). Pharmacological profle of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ter 334:171-181.
11. Ishiyama T, Tokuda K, Ishibashi T, Ito A, Toma S, Ohno Y. (2007). Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur J Pharmacol 572:160-170. (Pubitemid 47429645)
12. Koo TS, Kim SJ, Lee J, Ha DJ, Baek M, Moon H. (2011). Quantifcation of lurasidone, an atypical antipsychotic drug, in rat plasma with high performance liquid chromatography with tandem mass spectrometry. Biomed Chromatogr [Epub ahead of print, doi: 10.1002/bmc.1625]
13. Kusuhara H, Suzuki H, Terasaki T, Kakee A, Lemaire M, Sugiyama Y. (1997). P-Glycoprotein mediates the efux of quinidine across the blood-brain barrier. J Pharmacol Exp Ter 283:574-580. (Pubitemid 27514613)
14. Lee KR, Maeng HJ, Chae JB, Chong S, Kim DD, Shim CK, Chung SJ.(2010). Lack of a primary physicochemical determinant in the direct transport of drugs to the brain after nasal administration in rats: potential involvement of transporters in the pathway. Drug Metab Pharmacokinet 25:430-441.
15. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. (2009). Second-generation versus frst-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31-41.
16. Lieberman JA. (1993). Understanding the mechanism of action of atypical antipsychotic drugs. A review of compounds in use and development. Br J Psychiatry Suppl 7-18. (Pubitemid 23355884)
17. Meltzer HY. (1999). Treatment of schizophrenia and spectrum disorders: pharmacotherapy, psychosocial treatments, and neurotransmitter interactions. Biol Psychiatry 46:1321-1327.
18. Meyer JM, Loebel AD, Schweizer E. (2009). Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs 18:1715-1726.
19. Pang KS, Rowland M. (1977). Hepatic clearance of drugs. I. Teoretical considerations of a "well-stirred" model and a "parallel tube" model. Infuence of hepatic blood fow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 5:625-653. (Pubitemid 8253670)
20. van Os J, Kapur S. (2009). Schizophrenia. Lancet 374:635-645.